Convincing payers of drug cost-effectiveness is crucial for a profitable product. Predicting any potential pricing or…
You now have access to all the content in the PAREXEL Access Hub. We look forward to engaging with you.
We will be in touch shortly.
Please complete our registration form to continue.
This recent article published in DIA's Global Forum looks at the benefits and challenges of FDA's Accelerated Pathways. According to the FDA’s annual report, two-thirds of novel drugs approved in 2015 used at least one Accelerated Pathway, while a third used two or more.
In order to better understand how major US payers view Accelerated Pathways products, PAREXEL and the non-profit, non-partisan Network for Excellence in Healthcare Innovation (NEHI), conducted a survey of 20 national, regional, public, and private payers whose coverage decisions impact a total of 228 million patients. See the results and commentary in this short article.
Regulatory & Payer Submissions